Tokyo, Japan

Masae Kikuchi

This inventor holds 1 USPTO granted patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 1997.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masae Kikuchi: Innovator in Mycotic Disease Treatment

Introduction

Masae Kikuchi is a notable inventor based in Tokyo, Japan. She has made significant contributions to the field of medical science, particularly in the treatment of mycotic diseases. Her innovative work has led to the development of a unique patent that showcases her expertise and dedication to advancing healthcare.

Latest Patents

Masae Kikuchi holds a patent for "Caledothricins used in the treatment of mycotic diseases." This patent includes physiologically active caledothricins A-I and their salts, which are useful for treating various mycotic diseases. Additionally, her work involves strains belonging to the genus Pseudomonas that are capable of producing caledothricins upon cultivation. This patent highlights her innovative approach to addressing significant health challenges.

Career Highlights

Masae Kikuchi is associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. Her role at the company allows her to collaborate with other talented professionals and contribute to groundbreaking research and development in the field of medicine.

Collaborations

Masae has worked alongside notable colleagues, including Hitomi Tanaka and Hisao Shimada. These collaborations have further enriched her research and have played a crucial role in the advancement of her innovative projects.

Conclusion

Masae Kikuchi's contributions to the treatment of mycotic diseases through her patent demonstrate her commitment to innovation in healthcare. Her work not only reflects her expertise but also has the potential to impact the lives of many individuals suffering from these conditions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…